#fund-performance

#fund-performance

SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns? XPH holds 57 positions with relatively even weighting-no single stock exceeds 2.12% of the portfolio. That structure delivers pure-play pharma exposure spanning large-cap stalwarts like Eli Lilly and Company () and Merck & Co. (), mid-cap specialty pharmaceutical companies, and smaller biotech names focused on niche therapeutics.

Avala Global, launched by former Viking Global star trader Divya Nettimi, had strong performance numbers in 2025. However, the firm has continued to lose staff. Three investment analysts left in the second half of 2025, and Nettimi's fund is set to lose two more senior executives in 2026, including the firm's COO. Avala Global, the $2 billion manager launched by Nettimi in late 2022, gained 22.1% in 2025, according to the firm's year-end letter to clients, which was viewed by Business Insider.

Brevan Howard, the long-running macro investment manager with $33 billion in assets, finished 2025 looking up at many of its macro peers and multistrategy rivals. The firm's two largest funds - Alpha Strategies and Master, each of which runs roughly $11 billion - finished 2025 with gains of 8% and 0.8%, respectively, a person close to the firm told Business Insider. The firm's smaller Emerging Markets strategy was a bright spot, returning more than 15% over the year, the person added.

Out of more than 18,400 money managers worldwide, just 12.9% are women, compared with 12.5% last year and 10.3% in 2016. The absolute value of assets managed by women has tripled over the past ten years to £4 trillion, but this growth reflects a rise in mixed-gender teams, which now manage almost 15% of funds, up from just 6.7% a decade ago.